266 related articles for article (PubMed ID: 35185887)
1. Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.
Zheng G; Jia L; Yang AG
Front Immunol; 2022; 13():791975. PubMed ID: 35185887
[TBL] [Abstract][Full Text] [Related]
2. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
Zheng G; Guo Z; Li W; Xi W; Zuo B; Zhang R; Wen W; Yang AG; Jia L
Signal Transduct Target Ther; 2021 Jun; 6(1):236. PubMed ID: 34158475
[TBL] [Abstract][Full Text] [Related]
3. The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion.
Ueshima C; Kataoka TR; Hirata M; Furuhata A; Suzuki E; Toi M; Tsuruyama T; Okayama Y; Haga H
Cancer Immunol Res; 2015 Aug; 3(8):871-80. PubMed ID: 25735953
[TBL] [Abstract][Full Text] [Related]
4. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.
Rajagopalan S; Long EO
J Exp Med; 1999 Apr; 189(7):1093-100. PubMed ID: 10190900
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer.
Wiśniewski A; Kowal A; Wyrodek E; Nowak I; Majorczyk E; Wagner M; Pawlak-Adamska E; Jankowska R; Ślesak B; Frydecka I; Kuśnierczyk P
Tissue Antigens; 2015 Jun; 85(6):466-75. PubMed ID: 25855135
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of KIR2DL4 (CD158d), a putative NK cell receptor for HLA-G, does not influence susceptibility to asthma.
Le Page ME; Goodridge JP; Zhang G; Holt PG; Sly P; Witt CS
Tissue Antigens; 2013 Oct; 82(4):276-9. PubMed ID: 24033084
[TBL] [Abstract][Full Text] [Related]
7. Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations.
Le Page ME; Goodridge JP; John E; Christiansen FT; Witt CS
J Immunol; 2014 Jan; 192(2):732-40. PubMed ID: 24337374
[TBL] [Abstract][Full Text] [Related]
8. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?
Attia JVD; Dessens CE; van de Water R; Houvast RD; Kuppen PJK; Krijgsman D
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213057
[TBL] [Abstract][Full Text] [Related]
9. The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.
Moradi S; Berry R; Pymm P; Hitchen C; Beckham SA; Wilce MC; Walpole NG; Clements CS; Reid HH; Perugini MA; Brooks AG; Rossjohn J; Vivian JP
J Biol Chem; 2015 Apr; 290(16):10460-71. PubMed ID: 25759384
[TBL] [Abstract][Full Text] [Related]
10. HLA-G-mediated NK cell senescence promotes vascular remodeling: implications for reproduction.
Rajagopalan S
Cell Mol Immunol; 2014 Sep; 11(5):460-6. PubMed ID: 24998350
[TBL] [Abstract][Full Text] [Related]
11. Lack of KIR2DL4 gene in a fertile Caucasian woman.
Nowak I; Majorczyk E; Płoski R; Senitzer D; Sun JY; Kuśnierczyk P
Tissue Antigens; 2011 Aug; 78(2):115-9. PubMed ID: 21623736
[TBL] [Abstract][Full Text] [Related]
12. Rapid production of human KIR2DL4 extracellular domain and verification of its interaction with HLA-G.
Yu YR; Tian XH; Wang Y; Feng MF
Biochemistry (Mosc); 2006; 71 Suppl 1():S60-4, 4-5. PubMed ID: 16487070
[TBL] [Abstract][Full Text] [Related]
13. KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
Feng Z; Huang P; Zhang J; Xia X; Zhang AM; Zeng T; Chen Q; Zhu C; Tan W; Zhang Y; Yue M
J Med Virol; 2023 Mar; 95(3):e28645. PubMed ID: 36890645
[TBL] [Abstract][Full Text] [Related]
14. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential.
Faure M; Long EO
J Immunol; 2002 Jun; 168(12):6208-14. PubMed ID: 12055234
[TBL] [Abstract][Full Text] [Related]
15. The Influence of Cytomegalovirus on Expression of HLA-G and its Ligand KIR2DL4 by Human Peripheral Blood Leucocyte Subsets.
Albayati Z; Alyami A; Alomar S; Middleton D; Bonnett L; Aleem S; Flanagan BF; Christmas SE
Scand J Immunol; 2017 Nov; 86(5):396-407. PubMed ID: 28817184
[TBL] [Abstract][Full Text] [Related]
16. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells.
Yusa S; Catina TL; Campbell KS
J Immunol; 2002 May; 168(10):5047-57. PubMed ID: 11994457
[TBL] [Abstract][Full Text] [Related]
17. β2-Microglobulin-free HLA-G activates natural killer cells by increasing cytotoxicity and proinflammatory cytokine production.
Zhao L; Purandare B; Zhang J; Hantash BM
Hum Immunol; 2013 Apr; 74(4):417-24. PubMed ID: 23228393
[TBL] [Abstract][Full Text] [Related]
18. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition.
Yan WH; Fan LA
Cell Res; 2005 Mar; 15(3):176-82. PubMed ID: 15780179
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4-mediated responses.
Brusilovsky M; Cordoba M; Rosental B; Hershkovitz O; Andrake MD; Pecherskaya A; Einarson MB; Zhou Y; Braiman A; Campbell KS; Porgador A
J Immunol; 2013 Nov; 191(10):5256-67. PubMed ID: 24127555
[TBL] [Abstract][Full Text] [Related]
20. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
LeMaoult J; Zafaranloo K; Le Danff C; Carosella ED
FASEB J; 2005 Apr; 19(6):662-4. PubMed ID: 15670976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
